Arrowhead Pharmaceuticals Announces closing of collaboration agreement with Amgen
Arrowhead pharmaceuticals, Inc. (NASDAQ: ARWR) announced that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA program has closed, following early termination of the waiting period.
About ARC-LPA
ARC-LPA is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. ARC-LPA is Arrowhead’s first drug candidate to use a subcutaneously administered delivery construct.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.